Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

One year outcomes of Percutaneous Deep Vein Arterialization in the Dutch LimFlow Registry.

Created on 30 Sep 2026

Authors

Dieder J Stolk, Michael J Nugteren, Daniel van den Heuvel, Jan-Willem H C Daemen, Bram Fioole, Çağdaş Ünlü, Gert Jan de Borst, Michiel A Schreve

Published in

Journal of vascular surgery. Sep 29, 2026. Epub Sep 29, 2026.

Abstract

Percutaneous deep venous arterialization (pDVA) offers an endovascular potential alternative to reduce the risk of major amputation in patients with chronic limb threatening ischemia (CLTI) with no standard revascularization options (NO-CLTI).
In this prospective, multicenter registry conducted in the Netherlands between May 2020 and June 2024, NO-CLTI patients underwent pDVA using the LimFlow™ system. The primary endpoint was amputation-free survival (AFS) at 12 months. Secondary outcomes included limb salvage, overall survival, patency, pain scores, wound healing, transcutaneous oxygen pressure (TcPO2), and quality of life (QoL).
A total of 26 limbs of 23 NO-CLTI patients (mean age 64 ± 12 years; 20 men) were included, all classified as Rutherford category 5 and 17 (77.3%) as Wound Ischemia and foot Infection (WIfI) stage 4. Thirteen (53.8%) patients suffered from diabetes mellitus and six (21.7%) from renal insufficiency. Technical success was 100%. AFS was 69.2%, limb salvage 80.8% and overall survival 88.5% at 12 months. Primary patency, primary assisted patency and secondary patency rates at 12 months were 6.6%, 27.3% and 35.7% respectively. Reinterventions were performed to maintain patency in 85% of the limbs and in 58% for maturation of the pDVA. Median time to wound healing was 6.9 months, with 73.4% healed at 12 months. Pain scores decreased significantly (p <.001) in 12 months. QoL improved from a mean of 37% to 68% on the VascuQoL-25, though these analyses were based on limited available data.
pDVA in NO-CLTI patients is safe and effective at 12 months, preventing major amputation and mortality in the majority of patients. QoL also appeared to improve following pDVA. These observations warrant confirmation in larger studies.

PMID:
42810697
Bibliographic data and abstract were imported from PubMed on 30 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement